comparemela.com
Home
Live Updates
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy : comparemela.com
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated...
Related Keywords
,
Julie Seidel
,
Whit Tingley
,
Wendy Ryan
,
Exchange Commission
,
Globenewswire Inc
,
Clinical Program
,
Securities Exchange
,
Genetic Medicines Manufacturing Center
,
Nasdaq
,
Corporate Communications
,
Drug Administration
,
Tenaya Therapeutics Inc
,
Leading Cause
,
Dangerous Condition Linked
,
Sudden Cardiac Arrest
,
Young People Estimated
,
Studies Demonstrated Robust Reduction
,
Ventricular Arrhythmias
,
Extended Survival
,
Knockout Models
,
Disease After
,
Investigational New Drug
,
Chief Medical
,
Orphan Drug Designation
,
Gene Therapy
,
Cellular Regeneration
,
Precision Medicine
,
Securities Act
,
Securities Exchange Act
,
Markets
,
comparemela.com © 2020. All Rights Reserved.